Substituted imidazole neuropeptide Y Y5 receptor antagonists

A compound having the structural formula

• or a pharmaceutically acceptable salt, solvate or N-oxide thereof, wherein
• X is ═CH— or ═N—;
• Y is 1 to 3 substituents independently selected from the group consisting of H, halogen, trihaloalkyl, C1-C6 alkyl, C1-C6 alkenyl, C3-C7-cycloalkyl, C1-C6 alkyl substituted by C3-C7-cycloalkyl, —OH, —O(C1-C6)alkyl, —SH, —S(C1-C6)alkyl, or —CN;
• R4 is hydrogen or C1-C6 alkyl;
• R5 is C1-C6 alkyl, aryl or heteroaryl;
• provided R4 and R5 are not both C1-C6 alkyl, and provided that when R4 is hydrogen, R5 is not C1-C6 alkyl;
• or R4 and R5 together are C3-C6 alkylene and together with the nitrogen to which they are attached form a 4-7 membered ring;
• or R4 and R5, together with the nitrogen to which they are attached, form a 5, 6 or 7-membered ring, wherein 1 or 2 ring members are independently selected from the group consisting of —O—, —S— and —NR12—;
• R7 is C1-C6 alkyl, C3-C7 cycloalkyl, benzyl, aryl, or heteroaryl;
• R8 is hydrogen, C1-C6 alkyl, —C(O)—(C1-C6 alkyl), —C(O)—(C3-C7 cycloalkyl), —C(O)-aryl, —C(O)-heteroaryl, —SO2—R7, aryl, heteroaryl, —CONR4R5 or —C(O)—O—(C1-C6)alkyl;
• R9 is 1 to 3 substituents independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, halogeno and —CF3;
• R12 is hydrogen, C1-C6 alkyl, —C(O)—(C1-C6 alkyl), —SO2—R7, R9-phenyl, —CONR4R5, —C(O)—O—(C1-C6)alkyl, —CHO, C3-C7 cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, benzyl, benzoyl, —C(O)(C3-C7)cycloalkyl, —C(O)(C1-C6)alkylphenyl, pyridylmethyl, —C(O)pyridyl, —C(O)N(di-(C1-C6)-alkyl) or 4-tetrahydropyranyl.